Buprenorphine Market, by Application (Analgesic and Opioid Antagonist), by Route of Administration (Injectables, Sublingual, and Transdermal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North Am

Buprenorphine Market, by Application (Analgesic and Opioid Antagonist), by Route of Administration (Injectables, Sublingual, and Transdermal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Buprenorphine is a synthetic opioid alkaloid thiamine derivative with around 25- 40 times more potency than morphine. It acts primarily on the central nervous system and indicated for treatment of moderate to severe pain, peri-operative analgesia and opioid dependence. It is marketed in various dosage forms such as injectables, sublingual tablets & spray, transdermal patches.
Market Dynamics
Increasing prevalence of chronic pain, trauma injuries is a major factor driving buprenorphine market growth. According to the National Health Interview Survey (NHIS) 2016, an estimated 50 million of the U.S. adults suffered with chronic pain and around 19.6 million has high impact of chronic pain. Moreover, government initiatives for combatting problem of substance dependency and drug abuse is expected to boost the market growth. For instance, in April 2013, the Republic of Philippines under the President Rodrigo Roa Duterte, designed anti-drug cleansing efforts in cooperation with government and non-government agencies.
However, lack of licensed physicians for prescribing buprenorphine can hinder the market growth. According to the American Journal of Preventive Medicine, in June 2018, less than 4% licensed physicians were approved to prescribe buprenorphine for opioid use disorder.
Key features of the study:
This report provides in-depth analysis of the global buprenorphine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global buprenorphine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global buprenorphine market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global buprenorphine market.
Detailed Segmentation:
Global Buprenorphine Market, By Application:
Analgesic
Opioid Antagonist
Global Buprenorphine Market, By Route of Administration:
Injectables
Sublingual
Transdermal Patches
Global Buprenorphine Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Buprenorphine Market, By Region:
North America
By Application:
Analgesic
Opioid Antagonist
By Route of Administration
Injectables
Sublingual
Transdermal Patches
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Application:
Analgesic
Opioid Antagonist
By Route of Administration
Injectables
Sublingual
Transdermal Patches
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Application:
Analgesic
Opioid Antagonist
By Route of Administration
Injectables
Sublingual
Transdermal Patches
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Application:
Analgesic
Opioid Antagonist
By Route of Administration
Injectables
Sublingual
Transdermal Patches
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Application:
Analgesic
Opioid Antagonist
By Route of Administration
Injectables
Sublingual
Transdermal Patches
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Application:
Analgesic
Opioid Antagonist
By Route of Administration
Injectables
Sublingual
Transdermal Patches
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Siegfried*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Sanofi
Johnson Matthey
Mallinckrodt
Noramco
Unichem Laboratories
Arevipharma GmbH
Resonance-labs
Sun Pharmaceutical Industries Ltd.
Rusan Pharma
Micro Orgo Chem
Faran Shimi Pharmaceutical Co.
“*” marked represents similar segmentation in other categories in the respective section.